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Abstract
Sickle cell disease (SCD) is a condition very common in the United States of America and 
its most common presenting symptom is pain related to vaso-occlusive events (VOE). 
The cost associated with healthcare for the sickle cell population exceeds 1 billion $USD 
yearly, and the majority of this cost is associated with admission related to vaso-occlusive 
events. With the increase longevity of patients with SCD, due to new therapies and vac-
cination against common infection related to SCD, the prevalence of older individuals 
experiencing VOE will likely increase. The psychological impact inflicted on patients 
with SCD can further complicate adequate care of patients experiencing acute or chronic 
pain and the latter must be taken into consideration when planning an optimal treatment 
regimen. This chapter reviews the short- and long-term management options of pain 
related to VOE, their limitations as well proposed regimen that could pave the way for 
the future of pain management of SCD.
Keywords: sickle cell anemia, sickle cell pain, sickle cell crises, sickle cell disease,  
vaso-occlusive event, sickle cell pain management, pain management
1. Introduction
Sickle cell disease (SCD) is a term used for a collective group of autosomal recessive disorders 
involving the abnormal structure of hemoglobin where both alleles of the beta chain of hemo-
globin gene are affected, and at least one of them being affected by a sickle cell mutation. This 
mutation results from a single nucleotide change (GAT  GTT) in the sixth codon of the first 
exon of the beta-globin gene, resulting in the substitution of glutamic acid to valine (HbS) [1]. 
When an individual inherits two sickle cell genes (one from each parent, Hb S/S), he or she 
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is affected with sickle cell anemia. The Hb S/S mutation is the most common form of SCD, it 
accounts for 60–70% of SCD in the United States. Other forms result from a coinheritance of 
an HbS allele with another abnormal β-globin chain, HbC (Hb S/C) and from a β-thalassemia 
(Hb S/β+, Hb S/β0) being the most common among others. The mutation results in a beta chain 
of the hemoglobin molecule that is more hydrophobic compared to its normal counterpart 
(HbB) and is prone to polymerization during episodes of lower oxygen tension, hypother-
mia or many other stressors. A deoxygenated hemoglobin B (HbB) of patients with SCD will 
aggregate along its molecular axis leading to distortion of the cell membrane and giving it a 
sickle shape appearance. A hallmark of sickle cell disease is intermittent vaso-occlusive events 
(VOE) and chronic hemolytic anemia. VOE in acute and chronic pain as well as organ damage 
most notably to the bones, spleen, liver, brain, lungs, kidneys and joints [2].
SCD is a disease that is mostly present in persons of African, Mediterranean, Middle Eastern 
and Indian ancestry but has been found in individuals of any ethnic background. The preva-
lence of sickle cell trait, among African Americans in the United States, is 10%, or 3.5 million 
people, leading to the incidence of SCD among this ethnic group of approximately 1 in 365 
live births. More than 100,000 individuals in the United States are estimated to suffer from 
SCD. In the United Kingdom, the prevalence is about 12,500 people. Globally, it is estimated 
that about 5–7% of the world’s population are carriers of the mutant hemoglobin gene [3, 4], 
most of which residing on the African continent. As a matter of fact, about 15 million Africans 
are affected by SCD, more than all other continents combined. And about 200–300,000 affected 
births per year occur on the African continent [4, 5], accounting for more than 75% of the 
SCD newborns worldwide. Globally, SCD is one the four most common autosomal recessive 
diseases along with cystic fibrosis, thalassemia and Tay-Sachs.
Although in some areas of the world, such as Western African countries, where new treat-
ment modalities are not as widely accessible, SCD accounts for as many as 16% of deaths in 
children under 5 years old, the death rate has remarkably been reduced in the United States 
in recent times. In fact, many children did not live to adulthood about half a century ago. With 
the emergence of hydroxyurea, new born screening, newer and better antibiotics as well as the 
introduction of the pneumococcal vaccine, the lifespan for sickle cell individuals in the United 
States has increased substantially to 48 years old for female and 42 years old for male. As a 
matter of fact, the median survival age of patients with SCD living between 1910 and 1950 was 
below 20 years of age [6]. By 1980, 50% of children survived beyond 20 years of age; and by 
2009, 85% of SCD affect patients did. In England, the trend for hospital admissions related to 
SCD has been on the rise; from 2001/2002 to 2009/2010, admissions with a diagnosis of SCD 
have risen by more than 50%.
The management of SCD is complex and multidisciplinary. Supportive management includes 
regular follow-ups with the healthcare providers, adequate diet and sleep. Symptomatic man-
agement targets symptoms of the disease and include blood transfusions, pain management, 
antibiotics for infections among many other possible treatments. Preventive managements 
include vaccinations, avoidance of stressors that triggers crisis, hydroxyurea treatment, trans-
fusion, etc. Abortive therapy is the attempt at preventing painful crisis from getting worse 
and leading to other complications. They include nitrous oxide and anti-adhesion factors. The 
ultimate goal is curative therapy, which can arise from stem cell transplantation, and gene 
therapy in the future. This chapter focuses solely on the pain management of patients with 
SCD and is divided into acute pain, chronic pain and neuropathic pain.
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2. Pathogenesis of sickle cell pain
Sickle cell related pain is classified into three categories: acute pain, chronic pain and neuro-
pathic pain [7]. Acute pain is, by far, the most commonly encountered type of pain by health-
care providers and is the precursor of chronic and neuropathic pain. The pathophysiology 
of sickle cell pain is still not completely understood but is thought to be initiated by stress/
deoxygenation leading to the polymerization of sickle Hb in the red blood cells (RBC) inside 
the micro and macro-vasculature. This causes the RBC to lose its deformability and adhere to 
together on the vascular endothelium that in turn gets activated. The latter participates in the 
recruitment of white blood cells (WBC), which further accentuates the existing vascular occlu-
sion and facilitates tissue ischemia and damage. The activation of endothelial cells along with 
the tissue damage provokes the release of inflammatory mediators (including arachidonic 
acid, histamines, bradykinin, H+, K+, cytokines, serotonin, substance P, leukotrienes among 
others) [8, 9]. The combination of tissue damage and the resulting secondary inflammatory 
process generated is thought to be the cornerstone of the pain perceived during VOE. They 
convert chemical and mechanical energy into electrochemical impulse. The release of inter-
leukin-1 activates the cyclo-oxygenase (COX) system that in turns converts arachidonic acid 
into prostaglandins E2 and I2. This inflammatory soup created interacts to permit and facili-
tate the transduction and transmission of the painful stimuli from the periphery the central 
nervous system via the nerve endings, spinal cord and the thalamus. Some of the mediators 
(Substance P and bradykinin) also cause vasodilatation and extravasation of fluid leading to 
focal edema and tenderness in the affected areas.
The peripheral nociceptors involved in the painful cascade send their signals via fast acting 
A-delta and slow acting C fibers to the dorsal horn of the spinal cord by means of the dorsal 
root ganglion. From the dorsal horn of the spinal cord, the pain signals travel contralaterally 
through the spinothalamic tract to the thalamus that in turn has multiple interconnections with 
other systems such as the limbic system (mediator of memory and emotion), the reward sys-
tem (mediator of pleasure and addiction) and the glia. The signals are then either facilitated or 
suppressed at the level of the spinal cord by different modulators. The N-methyl-D-aspartate 
(NMDA) receptor is probably the most important receptor involved in the facilitation of pain 
transmission. Other important modulators include endogenous endorphins, serotonin and 
norepinephrine. With knowledge of the implicated factors involved in sickle cell pain, better 
management can be made targeting the involved transmitters, receptors and modulators.
3. Acute pain: the vaso-occlusive event
The vaso-occlusive event (VOE) is the most common cause of morbidity in the patients with 
SCD [10]. VOE also account for the most common cause of hospital admissions and missed 
school days. Some data report that up to 95% of hospital admissions related to SCD are for 
acute painful crises [11, 12]. Multicellular aggregates leading to blood flow obstruction in 
small blood vessels, depriving downstream tissues of oxygen and nutrient constitute the pain-
ful pathway of VOE, which was described earlier in this chapter. Although VOE-related pain 
can affect any part of the body and often cause generalized pain, it more commonly presents 
as pain in the extremities in the pediatric population, as opposed to being more commonly 
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seen as headache, chest pain, abdominal and back pain in older individuals [13]. The average 
duration of an acute pain crisis, based on hospital length of stay, is about 7 days [7]. Fever and 
leukocytosis typically accompany the patient’s presentation and the extent of WBC tends to 
correlate with the degree of pain [14, 15]. Also, the higher the level of Hb and hematocrit is, 
the more likely it is that a VOE will occur [9]. Even if leukocytosis associated with VOE does 
not necessarily signify an infectious process, careful evaluation should be undertaken, as these 
individuals are highly susceptible to pathogens. A careful and thorough history and physi-
cal examination should be undertaken. Inquiring about the onset, location, radiation, quality, 
relieving and aggravating factors associated with the current painful episode, any differences 
between the current episode and previous episodes, the presence of fever, transfusion history, 
medications, baseline hemoglobin level, and a thorough physical exam can assist in making 
a more definite diagnosis. Any atypical presentation should prompt further investigation 
(Table 1). The triggers of VOE can be physical, psychological, physiological and environmen-
tal among many. At any age group, a painful crisis typically begins with sudden onset of pain.
Although most individuals with SCD presenting to the healthcare professional with VOE will 
exhibit different types complains as far as onset, location, quality and intensity of their pain, 
the painful crisis will typical last between 7 and 10 days and can be described as possessing 
four different phases: A prodromal phase, initial phase, established phase and resolving phase 
[16–18]. A prodromal phase lasts 1–2 days and consists of aches, numbness or paresthesia in 
the area that will subsequently become painful. Physical signs of the prodromal phase include 
loss of usual appearance of the eyes (loss of luster or yellowing of the eyes). Laboratory values 
are significant for a decrease in erythrocyte deformability and increase density of erythrocytes. 
The second phase, initial phase, also lasting 1–2 days, is characterized by an increase in pain 
level and laboratory findings such as decreased RBC deformability, increase in the number 
of dense cells, red cell distribution width (RDW), reticulocytosis, leukocytosis, and relative 
1. Detailed history:
• Pain: onset, location, radiation, quality, frequency, progressiveness, alleviating and aggravating factors, 
home medications.
• Presence of fever
• Transfusion history
• Baseline hemoglobin
• Associated factors (Cough and respiratory symptoms, GI symptoms, neurological changes)
2. Thorough physical exam
• Body temperature
• Areas of tenderness
• Cardiac, pulmonary, skin, CNS, abdominal
3. Laboratory results (BMP, CBC)
4. Radiologic imaging based on history and physical (i.e., Abdominal CT for abnormal abdominal pain, Head CT if 
any CNS manifestation present)
5. Initiate pain management algorithm (Figure 1) after serious complications rules out (stroke, acute chest 
syndrome, splenic sequestration, pneumococcal sepsis, priapism)
Table 1. Primary investigation upon initial presentation of a SCD patient in pain.
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thrombocytopenia. The third phase, the established phase, is when the pain level is at its peak. 
The patient will show signs of frustration, depression, will tend to complain about hospital staff 
due to lack of appropriate treatment. Physical exam will show an elevated temperature, signs 
of inflammation, joint effusions. Laboratory signs will consist of elevated WBC, decreased Hb, 
and elevated reticulocyte count, elevated LDH, CPK and CRP. This phase is the longest for an 
average of about 4–5 days. The fourth and final phase, lasting 3 days on average, is the resolving 
phase; patients start showing signs of decreasing pain, RBC deformability increases, as well as 
fibrinogen, orosomucoid, ESR, platelets and plasma viscosity. The blood level of sickled RBC is 
decreased during the final phase. The increase in plasma viscosity leads to a hypercoagulable 
state that becomes a culprit for recurrence of another painful crisis. In fact, about 16% of hospital 
admissions because of VOE get readmitted with recurrence within 1 week of discharge [11, 19]. 
The reasons for readmissions include, but not limited to, withdrawal syndrome, premature 
discharge, inadequate pain management during hospital admission, development of tolerance 
to opioid medications, opioid-induced hyperalgesia (OIH). Analysis of children admitted to 
hospitals with VOE show that patients typically show a blunted response to pain relief after 
the fourth to sixth day of admission [20]. The reason for this phenomenon is unknown but 
could be related to OIH, tolerance or provider inexperience with prolonged VOE pain. This 
subset of patients is more likely to return to the hospital and get readmitted. Special attention 
should be paid to readmitted patient since these tend a have a higher morbidity and mortality 
rate. Also, care should be taken not to under treat patients in the resolving phase of the VOE; 
Even if the pain seems to subside during this phase, it is important to continue aggressive pain 
management, provide patients with appropriate discharge instructions to avoid overdose or 
withdrawal after discharge, arrange for appropriate follow-up.
This table points out important factors to consider when doing a primary investigation of a 
SCD patient presenting to the ED in pain. It is important to perform a full assessment of the 
patient to rule out any serious adverse events that are commonly associated with SCD.
3.1. Treatment of acute sickle cell pain
The first time SCD was recognized as its own disease was in 1910 when a medical resident 
observed the sickle appearing cell under a microscope [21]. Since then, many more discoveries 
about the disease were made, and its treatment still remains a dynamic process with changes 
constantly occurring. The therapeutic research initially consisted of finding ways to prevent 
the blockage of small blood vessels by the sickles shape RBC [22]. It was not until the 1960s that 
pain was recognized as a major symptom in SCD. Among the first pharmacological approaches 
used to treat it figured papaverine and acetaminophen [23]. It was not until later that opioid 
medications were used for the treatment of SCD and now represents the cornerstone of treat-
ment for acute painful crisis. Appropriate treatment of VOE crisis is crucial since the conse-
quences associated with the latter are many. Those involve acute chest syndrome in about 50% 
of VOE-related hospitalization, acute multi-organ failure and sudden death [24–26]. Aborting 
the acute painful episode at the prodromal phase could potentially prevent or minimize tissue 
damage [16]. A wide range of treatment modalities exists for the treatment of acute sickle 
cell pain. Nonpharmacological approaches such as acupuncture, heat, ice, relaxation tech-
niques and hypnosis but are not covered in detail in this chapter [9, 27–30]. Pharmacological 
approaches for the treatment of VOE around the globe consist predominantly of opioid 
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analgesic including full agonists, partial agonists, mixed agonists-antagonists, antagonists but 
also include opioid adjuvants as well as nonopioid analgesics such NSAIDs, acetaminophen 
and other adjuvants [9]. As previously mentioned, VOE is the most common presentation (up 
to 90%) of patients with SCD to the healthcare facilities (i.e., Emergency Department). The first 
step in management focuses on immediate pain control with fluids and analgesics as evidence 
exists demonstrating that rapid and efficient control of acute pain related to VOE reduces pain 
scores, length of hospital stay, improve patient satisfaction [28, 31], reduce hospitalization in 
patients with SCD and also a decrease in the development of chronic pain syndromes, which 
is commonly seen in the sickle cell population [9, 32].
However, managing the pain could be more difficult than anticipated by the healthcare pro-
vider, as the SCD patient’s pain management differs from that of the rest of the population. 
Indeed, the patient with sickle cell disease tends to be more tolerant to opioid medications 
then the rest of the population due to chronic administration, VOE pain can appear out of pro-
portion for most providers and necessitates higher doses of narcotics which most emergency 
department providers are not accustom to administer. This underlines the reason why most 
patients with sickle cell disease report that their pain is undertreated in the emergency depart-
ment and that the providers lack understanding and compassion [9, 33–38]. Additionally, 
VOE-related pain more exaggerated than expected, every patient possesses his own unique 
sensation, perception and expression of pain.
Indicators of adequate VOE management consist, but not limited to, admission to the hospital 
(indicates poor pain control in the ED), readmission to the hospital (indicator that pain was 
not well controlled during hospital stay), length of stay (indicator of effective pain manage-
ment during hospital stay), pain intensity felt during ED visit or hospitalization (different pain 
measurement assessment available), patient and parents satisfaction, increase or decrease in 
VOE/SCD-related complications (Table 2).
The indicators of an effective treatment of SCD patients during their visit to the ED or admis-
sion to the hospital are shown here. Signs of ineffective treatment are admission from the ED 
to the hospital, readmission to the hospital after discharge, increased length of stay in the ED 
or the hospital, elevated pain assessment score, poor patient and/or parent satisfaction.
Facilities that have taken into account these indicators of effective VOE pain management 
have demonstrated benefice in rapid treatment of patients presenting to their healthcare facil-
ity with VOE with an individualized plan for each patient. An individualized plan results in 
decreased hospital admissions, readmissions, length of ED and hospitalization, substantial 
decrease in pain scores, increased patient and parent satisfaction. Although no single plan 
or approach is perfect for all patients, there are different algorithms that are available to the 
healthcare provider that serve as helpful guide for the patient presenting with VOE. Using 
an algorithm has shown to be simple, cost-effective and beneficial for the patient’s general-
ized well-being. Institutions that commonly encounter patients with VOE are encouraged to 
either follow an existing effective algorithm or create their own. Every patient presenting to 
the healthcare provider with VOE-related pain would require his or her own individualized 
treatment plan [39]. Our preferred algorithm is inspired by the American Pain Society and is 
detailed in the following paragraph.
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This figure outlines our guidelines for the recommendation of the treatment of VOE in the ED.
Alternatively, institution that do not typically encounter individuals with SCD and that do not 
have an algorithm in place for the management of a patient that presents to their healthcare 
facility for the first time should involve starting with the lowest dose for the shortest duration 
possible in order to control the symptoms if the pain is mild to moderate and the patient has 
not been opioid naïve [39]. If the pain is moderate to severe and the patient has previously 
attempted an opioid medication without relief, a higher dose of opioid is preferred. From 
that baseline, the physician should titrate the dose, and duration of the analgesic medications 
upwards until adequate pain relief is achieved. On the other hand, as discussed earlier, the 
patient who presents for a subsequent visit to the same healthcare facility should initially be 
restarted on the same analgesic regimen with which adequate pain relief was obtained in the 
previous visits for VOE crises.
Figure 1. Management of SCD patient presenting to the ED with VOE.
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Whenever initiating opioid analgesia, it is mandatory to monitor for respiratory and seda-
tion status. Useful questionnaires such as the Richmond Agitation Sedation Scale (RASS), the 
visual analogue scale (VAS) exist for sedation and pain assessment respectively. Respiratory 
status is typically monitored by pulse oximetry and visual assessment although some institu-
tion advocate for continuous end-tidal carbon dioxide monitoring (EtCO
2
), especially when 
using high doses of opioids.
The preferred and recommended primary pharmacological method to treat the VOE crises is 
the opioid analgesic route and the commonly used medications include codeine, morphine, 
hydromorphone, fentanyl, hydrocodone/acetaminophen, hydrocodone/ibuprofen, oxymor-
phone, oxycodone, methadone and diamorphine [9].
3.2. Opioid medications
The first opiate used for VOE in the ED was meperidine in the 1960s. At home, short-acting 
oxycodone with acetaminophen was the most often used home medication. Morphine sulfate 
then got FDA approval in the 1980s and became the opiate of choice for the management 
of VOE in the 1990s. Not only did morphine show improvement in pain management and 
decreased hospital admissions related to VOE, it also did not possess the feared seizure side 
effect related to the meperidine metabolites, Normeperidine. These metabolites reduce the 
seizure threshold and also accumulate in patient with renal insufficiency, a complication com-
monly seen in patients with SCD [40–42]. In today’s world though, as mentioned earlier, 
many different types of opioid are used effectively for the treatment of VOE-related pain but 
in the United States, intravenous hydromorphone is the drug most commonly used in the 
hospital setting and oral oxycodone as home prescription medications [43]. As a comparison, 
in the United Kingdom, intravenous morphine, diamorphine and oral oxycodone are the 
most commonly used pain medications for VOE pain.
Opioid agonists produce their effect by binding into μ receptors. The potency of a particular 
opioid is dependent on the binding affinity or strength with which that drug binds to its recep-
tors and there is a great amount of variability of potency between different opiates. For example, 
hydromorphone is 5–7 as potent as morphine while sufentanyl is 500–1000 as potent as mor-
phine. When an opiate binds to its receptors, it initiates a cascade of biochemical events that 
starts with activation of G-proteins, inhibition of adenylate cyclase activity and extrusion of K++ 
that result in hyperpolarisation of cell membranes, which delays or prevents the transmission of 
1. Admission to the hospital
2. Readmission to the hospital
3. Length of stay in the ED or hospital
4. Patient pain assessment (i.e., VAS, Baker-Wong faces scale)
5. Patient satisfaction
6. Parent satisfaction
Table 2. Indicators of effective/ineffective VOE treatment.
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painful stimuli. Additionally, there exists a multitude of different receptors that each mediates 
the desired analgesic differently. Thus, the response to opioids depends not only on the type of 
opioid used, but also on the number and activity of the opioid receptors that a certain patient has. 
An opioid that binds a low number of receptors and has poor affinity, for example, is unlikely 
to produce effective analgesia in certain patients even if the dose is high. On the other hand, an 
opioid binding to an elevated number of receptors and with moderate or high binding affinity 
would provide effective analgesia even if used in small doses. This is part of the reason, among 
many others, why there is an immense variability to the pain response in patients with SCD. A 
dose considered an under treatment for a particular patient could overdose another patient.
3.3. Opioids adverse events
Unfortunately, opioids are not without side effects. The long list of mild to moderate adverse 
effects includes pruritus, nausea, vomiting, constipation, urinary retention, seizures, hives and 
the notorious respiratory depression. As mentioned earlier, seizures are mostly associated with 
meperidine. Other opioids have also possessed a potential for albeit a lot smaller and thought 
to be derived from the neuroexcitation related to metabolite of the opiate. Opioid-induced pru-
ritus is one of the most prevalent complications with the use of opioids and is typically well 
controlled by either hydroxyzine, diphenhydramine, low dose naloxone and, now recognized 
as the most effective treatment, nalbuphine. The more serious complications, some of which 
are very popular topic of debates in the world today include addiction, tolerance, withdrawal, 
physical dependence and pseudoaddiction. A condition feared by many providers in today’s 
world is addiction; a condition that is influenced by genetic, psychological and environmental 
factors that lead to compulsive use despite harm. Opiates are strong stimulants of the reward/
pleasure system, increasing the level of dopamine in the system, which in turn enhances the 
desire to achieve the reward/pleasure. Addiction can ultimately lead to overdose and death. 
Tolerance, on the other hand, represents a state of adaptation in which exposure to the same 
amount of the drug results in a lower effect than previously obtained. Physical dependence also 
happens frequently and is the cause of the known withdrawal syndrome that manifests with 
abrupt cessation or an exaggerated reduction in the dose of opiate administered. Signs and 
symptoms of withdrawal include tremor, shakiness, anxiety, depression, lacrimation, rhinor-
rhea, fatigue, irritability, and diarrhea. Pseudoaddiction is very common in patients with SCD. It 
is a state, in which the patient appears to be seeking for excessive amount of medication, but is 
due to under-treatment of pain and resolves when the pain is treated properly. Opioid-induced 
hyperalgesia (OIH) results from chronic administration of opioid medications. A process that 
is not totally proven and well understood yet but is thought to result from a minor excitatory 
pathway that becomes magnified with chronic use of the opiates and, ultimately, becomes the 
dominant effect. The sites of pain from OIH are typically the same as the sites perceived during 
the VOE crisis, but the quality of the pain differs. It is more neuropathic in nature.
3.4. Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the main adjuvant of opioid in today’s 
therapeutic guidelines of most healthcare facilities. Ketorolac tromethamine is the NSAID 
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most commonly used for this purpose; it is commonly administered either intravenously or 
intramuscularly at a dose of 0.5 mg kg−1 for a maximum of 30 mg every 6 h for 5 days. NSAIDs 
partly inhibit the inflammatory cascade involved in VOE (see above). Although usually not 
sufficient to resolve a pain crisis as a sole treatment, it works synergistically with opioids. For 
moderate VOE pain, a single dose of 30 mg IV is typically sufficient. Opioids are limited by 
their propensity to cause gastritis and gastric bleeding. The drug should be used cautiously in 
patients with peptic ulcer disease or a history of gastrointestinal bleeding. NSAIDs can impair 
kidney function and accelerate the renal injury produced by sickle cell disease itself. For these 
reasons, many specialists avoid NSAIDs in patients with sickle cell disease.
3.5. Ketamine
Ketamine is gaining a lot of popularity for the treatment of VOE refractory to opioids. A lot of 
institutions have integrated its use in their algorithm of VOE treatment and strong evidence 
exists regarding its efficacy as an adjuvant to opioids and NSAIDs. Ketamine is a noncompeti-
tive antagonist at the N-methyl-d-aspartate (NMDA) receptor. This property has been shown 
to modulate opioid tolerance and opioid-induced hyperalgesia. The use of ketamine is limited 
by its psychiatric side effects such as hallucinations, abnormal dreams, nightmares and abnor-
mal behavior. Randomized controlled trials are still necessary for the regular implementation 
of ketamine in SCD protocols.
4. Pain management of patients with sickle cell disease with chronic 
and neuropathic pain
4.1. Chronic pain
In addition to the acute crises, patients with SCD also suffer from chronic pain, which often times 
overlap with acute pain crises and create difficulty in designing a treatment plan. These individ-
uals can find management of their pain very difficult and therefore change providers frequently, 
resulting in a higher degree of misdiagnosis and misperception of their pain. Identifying the 
presenting syndrome can help individualize a treatment plan and therefore understanding the 
signs and symptoms of chronic pain is crucial for aggressive and effective therapy.
Chronic pain is generally defined as pain that is present for 3 or more months. As opposed 
to the acute pain, which is sharp and throbbing in nature with a sudden onset, chronic pain 
is often vague, deep, and achy there is present for a longer period. Approximately 5–10% of 
adult patients with sickle cell disease are affected with chronic pain [44]. However, a recent 
study from Pain in Sickle Cell Epidemiology Study reported the incidence of chronic pain 
in 29% of 292 adult patients [45]. These patients tend to be older and use more opioids [46]. 
The chronic pain is categorized into two types. The first type is objective and is due to vis-
ible signs such as leg ulcers and avascular necrosis which is associated with deep somatic 
pain. The second type is due to recurrent acute attacks of painful crises. Failure to treat these 
acute attacks can lead to chronic pain syndrome and resultant neuropathic pain. The exact 
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pathophysiologic mechanism is not fully understood, however central component has been 
described in which the threshold for the perception of pain is lowered, resulting in pain from 
typically nonpainful stimuli (allodynia) and severe pain generated by mildly painful stimuli 
(hyperalgesia) (Figure 2).
This figure depicts the age distribution of SCD patient with chronic pain. As demonstrated by the 
figure, the larger proportion of SCD patients with chronic pain is between 20 and 29 years old.
4.2. Pathophysiology and mechanism
Although the exact mechanism underlying the transition from acute to chronic pain is not 
fully understood, some contributing factors include chronic inflammation, organ damage, 
and opioid-induced hyperalgesia [47]. According to a study presented at the Annual Meeting 
of American Society of Hematology, patients with chronic pain (defined as >50% of days 
reported as painful crises collected over 6 months) tend to be older (41 vs. 32 years), use more 
opioids (11.45 mg/day vs. 2.92 mg/day), and have higher levels of mast cell activation [48].
Opioid-induced hyperalgesia is a state of sensitization caused by repetitive exposure to opi-
oids resulting in paradoxical response to pain. Although there is no understanding or consen-
sus on the biomolecular mechanism, it is believed to be secondary to neuroplastic changes in 
the central and peripheral nervous system [49]. Despite it being a controversial topic, patients 
with sickle cell disease with chronic pain do require increasingly higher dosage adjustments.
Recent research demonstrates clear evidence that chronic inflammation and mast cell activa-
tion plays a role in the chronic pain state of patients with sickle cell disease. Mast cells release 
the neuropeptide substance P, which promotes neurogenic inflammation and nociceptive 
Figure 2. Distribution of SCD patient with chronic pain.
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activation [48]. Additionally, tryptase, a serine proteinase found within mast cells appears far 
more elevated in patients with chronic pain in sickle cell disease. This can help guide future 
therapy directed toward inhibition of mast cell activation, and implementation of medications 
such as Cromolyn. This can also help identify and diagnose patients with sickle crises who 
present to the emergency department and are sadly mistaken as drug seeking opportunists.
4.3. Treatment/management
The cornerstone to therapy involves recognition of the disease state and assessment of the pain 
intensity, which helps individualize therapy. Prevention of SCD pain is crucial by avoidance 
of precipitating factors (dehydration, infection, diuretics, altitude, acidosis, and hypoxia), as 
repetitive acute inflammation can result in chronic pain. The approach to pain management 
in patients with SCD with chronic pain is multidisciplinary, involving the use of pharmaco-
logic analgesic drugs, nerve blocks, physical therapy, and cognitive behavioral therapy [46]. 
Discussion of hydroxyurea and other disease modifying therapies is appropriate. Close atten-
tion should be made to psychosocial issues including depression and social isolation [45].
Mild chronic pain can be treated with acetaminophen or dihydrocodeine. In patients with 
liver failure, acetaminophen can be avoided and NSAIDS such as ibuprofen can be used, 
but should be used with caution in patients with borderline renal function or failure. In 
patients with moderate pain, consideration of slow release morphine with small amounts 
of rapid-release morphine for breakthrough pain is advised [46]. Alternatives to Morphine 
include hydromorphone, oxycodone, methadone, or transdermal fentanyl. Methadone in 
particular can be efficacious in patients with suspected opioid-induced hyperalgesia due to 
its N-methyl-D-aspartate (NMDA) antagonism and monoaminue uptake reuptake inhibition. 
In patients who cannot tolerate opioid side effects and have contraindications the prior listed 
opioid analgesics, tramadol, a selective Mu-receptor agonist and serotonin–norepinephrine 
reuptake inhibitor can be considered [44]. The goal of chronic pain management is to maxi-
mize the quality of life rather than short-term pain suppression [45]. Other adjuvants include 
partial opioid agonists such as buprenorphine, topical agents, corticosteroids, antihistamines, 
benzodiazepines, antidepressants, anticonvulsants, and phenothiazines.
In patients with severe chronic pain, alternative procedures can be considered in addition to 
opioid therapy. For example, in a patient with deep somatic pain of avascular necrosis of the 
hip, an interventional nerve block could supply instant relief for 12 h, and potentially 72 h 
if the injectate is liposomal Bupivacaine [49, 50]. Physiotherapy can help strengthen muscle 
fibers and loosen stiff joints, preventing contractures and physical disability. Psychological 
support with cognitive behavioral therapy can help the patient cope with pain or deal with 
the mental agony and psychosocial stressors associated with sickle cell disease [46]. Adapting 
to cognitive skills can also help alter the perception of pain as negative thinking has been 
linked to higher pain scores. Massage therapy, relaxation techniques, and even self-prayer 
have been reported in published studies to help with chronic pain [51]. The American Pain 
Society strongly recommends psychological, behavioral and physical modalities as necessary 
complements to pharmacologic therapy, as a significant effect on pain scores and activities 
of daily living have been reported [52]. Orthopedic devices for back or leg support can be 
deployed to reduce chronic pain in the hips or back. Orthopedic surgery, such as total hip 
replacement should be deferred until the pain is no longer tolerable [46].
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Lastly, it important to note that patients with SCD are not immune to non-hemoglobin-
opathic pain. Excluding other disease processes is essential and misdiagnosis can be life 
threatening. Conditions that can mimic the chronic pain state include but are not limited to 
ischemic colitis, pancreatitis, bone marrow infarction, hepatobiliary disorders, and vertebral 
body necrosis [53].
4.4. Neuropathic pain
In addition to acute and chronic pain, a neuropathic component of pain plays a large and 
undiagnosed constituent of chronic disease. Data suggest that the development of neuropathic 
pain is responsible for the transition from acute to chronic pain with aging [54]. The general 
understanding is that multiple components of central sensitization and peripheral nerve 
injury are responsible. Types of neuropathic pain include peripheral neuropathic (caused by 
vaso-occlusive crises and neuropathies) and central neuropathic (caused by CNS damage, 
ictus, and central sensitization). Peripheral nerve injury and prostaglandin release can sensi-
tize peripheral nerve endings and facilitate the transmission of pain along the A-delta and C 
fibers to the cerebral cortex [44]. The exact mechanism, however, is poorly understood, which 
hinders our progression toward achieving novel therapies.
Neuropathic pain from SCD occurs more commonly in older adults and females, which is 
hypothesized to be secondary to abnormalities in pain signaling pathways. These patients 
have extreme sensitivity to tactile touch (allodynia), increased pain from a normally painful 
stimulus (hyperalgesia) and extreme sensitivity to temperature [45]. Some studies demon-
strate the prevalence to be approximately 20% of the chronic pain population. In a 2013 article 
published in Pediatric Blood and Cancer, 37% of patients with SCD were identified to have 
neuropathic pain and only 5% were reported to be taking a neuropathic pain drug (gabapen-
tin), which highlights the lack of diagnosis and treatment [55]. Thus, appropriate screening 
tools such as the pain DETECT questionnaire could help identify patients with neuropathic 
pain and help initiate treatment.
4.5. Treatment/management
Although no single treatment therapy exists, a multimodal pharmacologic approach can 
be instituted in patients diagnosed with neuropathic pain. Treatment may include tricyclic 
antidepressants (TCA, SSRI, SNRIs, MAOIs) or anticonvulsants (pregabalin, gabapentin), 
although there is no data supporting its use in patients with SCD [56]. With a better safety 
profile and less side effects than opioids, tramadol (a typical analgesic with weak opioid 
receptor agonism and SNRI activity) can act centrally and be helpful in treating neuropathic 
pain, but should be used with caution in patients with renal failure [57, 58].
5. Future of SCD pain treatment
Until SCD can be fully cured (possibly with gene therapy), new and improved treatment 
modalities are necessary. The information currently available about SCD is that rapid and 
aggressive therapy at the first sign of a VOE help reduce the length of the event and even 
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abort it. Currently, patients with VOE receive treatment 2–3 days after the onset of the 
prodromal signs [16]. Measurement should be made in the future to offer patients with 
SCD methods of treatment available at home such as opioids (IV or IM), supplemental 
oxygen, and rapid hydration methods. Anti-inflammatory agents and oral opioids rep-
resent the current home treatment modalities. Vasodilators also represent a fundamen-
tal therapeutic weapon for VOE, especially when used early. Administration of nitric 
oxide (NO) in the emergency department has shown to abort the crisis in some patients; 
however, no benefice was found when NO was used during the hospital stay [59–61]. 
Perhaps NO could be offer as a home medication and its use would be even earlier than 
it would be in the ED. Recently, reports have emerged of small doses of opioid antagonist 
in combination with an agonist enhanced the analgesic effect and delayed the develop-
ment of tolerance [62]. Recent trials targeting the inhibition of the capsaicin receptor tran-
sient receptor potential vanillin 1 (TRPV1) showed promising results in relieving pain in 
patients with SCD [63].
6. Conclusion
Although many complications stem from SCD, leading to a significantly reduced lifespan, 
pain remains the most cardinal sign of the disease and is still inappropriately treated. The 
main explanations for the inadequate treatment are the providers’ lack of knowledge about 
the disease and its narcotic requirement, lack of institutional treatment protocol in place and 
lack of patient education. The most important factors about the treatment, to our knowledge, 
are rapid and aggressive treatment as soon as signs of VOE happen, adequate rehydration 
and oxygenation. The treatment modalities have evolved enormously since the discovery of 
the disease and hopes for future treatment are bright.
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